<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T09:18:05Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/67408" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/67408</identifier><datestamp>2026-05-15T19:51:56Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Thornlow, Dana</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair">Alabi, Christopher Akinleye</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Putnam, David A.</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember">Brown, William J.</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2019-10-15T15:31:18Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2019-10-15T15:31:18Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2019-05-30</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 11333</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 13815198</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/67408</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/v8cw-xn74</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">11050390</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Monoclonal antibodies (mAbs) have emerged over the last 20 years as an invaluable biosensing, diagnostic, and therapeutic tool for targeting cancer. With their tight antigen binding and specificity, mAbs are a modular platform for a host of therapeutic modalities, most recently in bioconjugates. Bioconjugates are broadly defined as biological targeting moieties covalently linked with therapeutic molecules and are useful in targeting potent therapeutics to specific cells and tissues. In this work, we develop and investigate mAb bioconjugates for targeted delivery of small molecules, nucleic acids, peptides, and proteins. First, we establish methods for in-house expression, purification, and characterization of mAbs that undergo lysosomal and fast recycling endocytosis pathways upon binding to a target antigen. We then utilize biorthogonal reaction pairs to append various cargo to the mAbs. With an eye toward short-interfering RNA (siRNA) delivery, we conjugate siRNA and membrane disrupting agents to antibodies for co-delivery, targeted cytosolic localization, and gene knockdown of a luciferase reporter gene. Finally, we engineer antibodies with two, orthogonal conjugation sites and to attach sequentially cleavable cargos to a single mAb. With this, we demonstrate controlled, site-specific, dual-labeled antibodies with extracellular and intracellular cargo release mechanisms that can be implicated for sequential release antibody drug conjugates (ADCs).</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="subject">Chemical engineering</dim:field>
   <dim:field mdschema="dc" element="subject">Antibody</dim:field>
   <dim:field mdschema="dc" element="subject">Antibody drug conjugate</dim:field>
   <dim:field mdschema="dc" element="subject">Bioconjugation</dim:field>
   <dim:field mdschema="dc" element="subject">LAP tag</dim:field>
   <dim:field mdschema="dc" element="subject">Microbial Transglutaminase</dim:field>
   <dim:field mdschema="dc" element="subject">siRNA</dim:field>
   <dim:field mdschema="dc" element="title">Antibody Bioconjugates for Targeted Therapeutic Delivery</dim:field>
   <dim:field mdschema="dc" element="type">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Chemical Engineering</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph.D., Chemical Engineering</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Thornlow, Dana</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="3454d44a-a4b9-4b08-9a32-60016bfccd81">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en_US&lt;/Language>
   	&lt;Title>Antibody Bioconjugates for Targeted Therapeutic Delivery&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2019-05-30&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/v8cw-xn74&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Thornlow, Dana&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;Keyword>Chemical engineering&lt;/Keyword>
    &lt;Keyword>Antibody&lt;/Keyword>
    &lt;Keyword>Antibody drug conjugate&lt;/Keyword>
    &lt;Keyword>Bioconjugation&lt;/Keyword>
    &lt;Keyword>LAP tag&lt;/Keyword>
    &lt;Keyword>Microbial Transglutaminase&lt;/Keyword>
    &lt;Keyword>siRNA&lt;/Keyword>
   	&lt;Abstract>Monoclonal antibodies (mAbs) have emerged over the last 20 years as an invaluable biosensing, diagnostic, and therapeutic tool for targeting cancer. With their tight antigen binding and specificity, mAbs are a modular platform for a host of therapeutic modalities, most recently in bioconjugates. Bioconjugates are broadly defined as biological targeting moieties covalently linked with therapeutic molecules and are useful in targeting potent therapeutics to specific cells and tissues. In this work, we develop and investigate mAb bioconjugates for targeted delivery of small molecules, nucleic acids, peptides, and proteins. First, we establish methods for in-house expression, purification, and characterization of mAbs that undergo lysosomal and fast recycling endocytosis pathways upon binding to a target antigen. We then utilize biorthogonal reaction pairs to append various cargo to the mAbs. With an eye toward short-interfering RNA (siRNA) delivery, we conjugate siRNA and membrane disrupting agents to antibodies for co-delivery, targeted cytosolic localization, and gene knockdown of a luciferase reporter gene. Finally, we engineer antibodies with two, orthogonal conjugation sites and to attach sequentially cleavable cargos to a single mAb. With this, we demonstrate controlled, site-specific, dual-labeled antibodies with extracellular and intracellular cargo release mechanisms that can be implicated for sequential release antibody drug conjugates (ADCs).&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>